Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014).

scientific article published on 7 November 2017

Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/RHEUMATOLOGY/KEX412
P932PMC publication ID5850281
P698PubMed publication ID29121273

P50authorYuqing ZhangQ43157198
P2093author name stringHyon K Choi
Na Lu
Sharan K Rai
April M Jorge
P2860cites workCurrent and emerging treatment options in the management of lupusQ26741266
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateQ26859134
Treatment of lupus nephritis: current paradigms and emerging strategiesQ39138845
Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012.Q40126330
Incidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American College of Rheumatology and the 2012 Systemic Lupus International Collaborating Clinics classification criteriaQ40672396
Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysisQ40817900
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled studyQ41418810
The bimodal mortality pattern of systemic lupus erythematosusQ43703475
Hydroxychloroquine: the cornerstone of lupus therapyQ46643929
Additive Interaction in Survival AnalysisQ57167120
Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality ratesQ64111108
Mortality studies in SLE: how far can we improve survival of patients with SLEQ80533656
Approaches for estimating minimal clinically important differences in systemic lupus erythematosusQ27021623
From patient care to research: a validation study examining the factors contributing to data quality in a primary care electronic medical record databaseQ30887394
Life expectancy of different ethnic groups using death records linked to population census data for 4.62 million people in ScotlandQ31118445
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritisQ33505914
Adaptation and validation of the Charlson Index for Read/OXMIS coded databasesQ33522043
Validation and validity of diagnoses in the General Practice Research Database: a systematic reviewQ33588222
The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population-based studyQ33822203
Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health studyQ34017775
Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk Arthritis Register.Q34481954
Selection bias in rheumatic disease researchQ34662693
Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decadesQ35551526
Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United StatesQ35567251
Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosusQ35879759
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trialQ35993027
The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritisQ36014587
Malignancies in systemic lupus erythematosus: a 2015 updateQ36035448
Inequalities in healthy life expectancy between ethnic groups in England and Wales in 2001.Q36288487
The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012.Q36475637
The frequency and outcome of lupus nephritis: results from an international inception cohort studyQ37082037
Improved survival in rheumatoid arthritis: a general population-based cohort studyQ37531008
Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohortQ37684625
Death rates in England and Wales and the United States: variation with age, sex, and raceQ37705578
Infections in systemic lupus erythematosusQ37800299
Management of pregnancy in systemic lupus erythematosusQ38036105
The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic reviewQ38082909
Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapyQ38095862
Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategiesQ38149856
Treatment of severe lupus nephritis: the new horizon.Q38271125
Advances in use of immunomodulatory agents--a rheumatology perspectiveQ38431512
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab studyQ38466691
Mortality in systemic lupus erythematosusQ38467155
Risk of Myocardial Infarction and Stroke in Newly Diagnosed Systemic Lupus Erythematosus: A General Population-Based Study.Q38764974
Success and failure of biological treatment in systemic lupus erythematosus: A critical analysisQ38884826
Impact of systemic lupus erythematosus on maternal and fetal outcomes following pregnancy: A meta-analysis of studies published between years 2001-2016.Q38931444
P433issue2
P921main subjectsystemic lupus erythematosusQ1485
P304page(s)337-344
P577publication date2017-11-07
P1433published inRheumatologyQ7320492
P1476titleUnchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014).
P478volume57

Reverse relations

cites work (P2860)
Q55401570Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus.
Q89927588Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study
Q90391852Changing trends in mortality in systemic lupus erythematosus? An analysis of SLE inpatient mortality at University Hospital Coventry and Warwickshire NHS Trust from 2007 to 2016
Q89486568Characteristics and Symptom Severity of Patients Reporting Systemic Lupus Erythematosus in the PatientsLikeMe Online Health Community: A Retrospective Observational Study
Q92540430Epidemiology and outcomes of sepsis among hospitalizations with systemic lupus erythematosus admitted to the ICU: a population-based cohort study
Q58608203Hydroxychloroquine retinopathy - implications of research advances for rheumatology care
Q90412368New therapeutic strategies in systemic lupus erythematosus management
Q92404993Novel Methods of Incorporating Time in Longitudinal Multivariate Analysis Reveals Hidden Associations With Disease Activity in Systemic Lupus Erythematosus
Q98736004The Epidemiology and Outcomes of Mental Disorders in Critically Ill Patients With Systemic Lupus Erythematosus: A Population-Based Study
Q91803860The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts

Search more.